دورية أكاديمية

Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function.

التفاصيل البيبلوغرافية
العنوان: Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function.
المؤلفون: Park, Maria, Suein Choi, Sungpil Han, Wonsuk Shin, Anhye Kim, Seunghoon Han, Bomin Kim, Yeji Lim, Hyounggyoon Yoo
المصدر: Translational & Clinical Pharmacology; Dec2023, Vol. 31 Issue 4, p226-237, 12p
مصطلحات موضوعية: KIDNEY physiology, PREGABALIN, PHARMACOKINETICS, CONTROLLED release preparations, CONFIDENCE intervals
مستخلص: A new sustained-release (SR) pregabalin tablet, YHD1119, was formulated for once-daily dosing. In the current study, we aimed to evaluate the pharmacokinetics of YHD1119 tablets in patients with reduced renal function. Subjects were grouped by creatinine clearance: > 60 mL/min/1.73m² (Cohort A) and 30-60 mL/min/1.73m² (Cohort B). Eight subjects in Cohort A received a YHD1119 75 mg tablet (Y75T) and a YHD1119 150 mg tablet (Y150T) in each period, and eight subjects in Cohort B received a Y75T. Non-compartment analysis and population pharmacokinetic analysis using a one-compartment model with first-order elimination and first-order absorption with lag time were performed. Sixteen subjects completed the study. The geometric mean ratio (GMR) (90% confidence intervals [CI]) for maximum concentration (Cmax), and area under the concentration-time profile from 0 to the last measurable time (AUClast) after Y75T of Cohort B to those of Y75T of Cohort A were 1.2273 (1.0245-1.4701), and 2.4146 (1.8142-3.2138), respectively. The GMR (90% CI) for Cmax, and AUClast after Y75T of Cohort B to those of Y150T of Cohort A were 0.6476 (0.5229-0.8021), and 1.1471 (0.8418-1.5632), respectively. Simulated steady-steady pregabalin concentrations after once-daily Y75T dosing in subjects with eGFR 45 mL/min/1.73 m² were within the range of steady-state concentrations simulated after once-daily Y150T dosing in subjects with eGFR 90 mL/min/1.73 m². The total pregabalin exposure of Y75T in patients with moderate renal impairment was comparable with that of Y150T in subjects with near-normal renal function. [ABSTRACT FROM AUTHOR]
Copyright of Translational & Clinical Pharmacology is the property of Korean Society for Clinical Pharmacology & Therapeutics and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:22890882
DOI:10.12793/tcp.2023.31.e20